Elevated protein kinase C alpha expression may be predictive of tamoxifen treatment failure

• Type of Material: Article
• Authors: D.A. Tonetti, University of Illinois; M. Morrow, Northwestern University; N. Kidwai, Northwestern University; A. Gupta, Northwestern University; Sunil Badve, Emory University
• Language: English
• Date: 2003-05-06
• Publisher: NATURE PUBLISHING GROUP
• Publication Version: Final Published Version
• Copyright Statement: © 2003 Cancer Research UK.
• License: Creative Commons Attribution 4.0 International
• Final Published Version (URL): http://dx.doi.org/10.1038/sj.bjc.6600923
• Title of Journal or Parent Work: BRITISH JOURNAL OF CANCER
• Volume: 88
• Issue: 9
• Start Page: 1400
• End Page: 1402
• Grant/Funding Information: These studies were supported by NIH/NCI Grant R01CA79847 and the Avon Foundation awarded to DAT.
• Keywords: ESTRADIOL HYPERSENSITIVITY; breast cancer; Science & Technology; BREAST-CANCER CELLS; tamoxifen resistance; IN-VIVO; DNA-BINDING; Life Sciences & Biomedicine; ATHYMIC MICE; Oncology; protein kinase C alpha; TUMORS; ESTROGEN DEPRIVATION
• Research Categories: Health Sciences, Oncology; Health Sciences, Obstetrics and Gynecology

Abstract

We previously reported that stable transfection of protein kinase C alpha (PKCα) into T47D human breast cancer cells results in tamoxifen (TAM)-resistant turnout growth. Relevance of PKCα expression in clinical specimens was determined by comparing PKCα expression in tumours from patients exhibiting disease recurrence with patients remaining disease-free following TAM treatment. Our results suggest that PKCα expression may predict TAM treatment failure.